熱點掃描 | 醫藥外包概念走弱，藥明生物、藥明康德跌超6%
uSMART盈立智投5月5日消息，截止發稿，港股三大指數齊漲，恆生指數上漲0.7%，報21018.64點，成交額541.19億；國企指數上漲0.9%，報7204.09點，成交額209.24億；紅籌指數上漲0.03%，報3934.28.點，成交額27.19億。
手遊股齊漲，嗶哩嗶哩漲超5%，飛魚科技漲近5%，金山軟件漲超%，中手遊、心動公司跟漲；
黃金及貴金屬板塊漲幅居前，紫金礦業漲超2%，中國白銀集團、山東黃金漲近2%，中國黃金國際漲1.59%；
電力股普跌，華能國際電力股份、華潤電力跌逾2%，中國電力跌1.3%，大唐發電、華電國際電力股份跟跌；
醫藥外包概念持續走弱，藥明生物、藥明康德跌超6%，昭衍新藥跌3%，康龍化成跌超2%，維亞生物、金斯瑞生物科技跌逾1%；
航空股走勢分化，美蘭空港、國泰航空漲近3%，中國國航跌2.24%，中國南航、中國東航跌超1%；
熱門股
新華製藥拉昇漲8.64%，報7.17港元，成交額放大至7897萬港元，總市值48億港元。新華製藥A股目前錄得5連板漲停，股價創逾12年新高價。4月27日，公司與真實生物簽署《戰略合作協議》，成功奪取阿茲夫定產銷權，業內指或迎來新利潤增長點。值得注意的是，此前一季報數據顯示，淨利潤同比大降99.99%至1.09億元；
長飛光纖光纜快速拉昇漲近4%，現報11.06港元。瑞信研報指，上調公司2022-24年每股盈利預測1%-2%，以反映一季表現勝於預期和較好營運開支，看好行業情緒改善、多元化策略、新業務貢獻和風險回報，目標價由13.4港元至13.6港元，維持跑贏大市評級。
百濟神州漲2.54%，報98.9港元，總市值1345億港元。該公司昨日宣佈中國國家藥品監督管理局(NMPA)已批準倍利妥(注射用貝林妥歐單抗，BLINCYTO)用於治療兒童復發或難治性(R/R)CD19陽性的前體B細胞急性淋巴細胞白血病(ALL)。此前，倍利妥已於2020年12月獲得NMPA附條件批準，用於治療這一適應症的成人患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
